Rociletinib: has the TIGER lost a few of its stripes?

被引：22

作者：

Dhingra, K. ^{[1
]}

机构：

[1] KAPital Consulting LLC, Sparta, NJ USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷 / 06期

关键词：

D O I：

10.1093/annonc/mdw140

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This case study of rociletinib, once considered a highly promising drug and now facing significant hurdles for marketing approval, should serve as a cautionary tale for pharmaceutical and biotech companies as well as academic investigators on the dos and don'ts of drug development.

引用

页码：1161 / 1164

页数：4

共 4 条

[1] Oncology 2020: a drug development and approval paradigm [J].

Dhingra, K. .

ANNALS OF ONCOLOGY, 2015, 26 (11) :2347-2350

[2] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[3] Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer [J].

Sequist, L. V. ;

Soria, J-C ;

Goldman, J. W. ;

Wakelee, H. A. ;

Gadgeel, S. M. ;

Varga, A. ;

Papadimitrakopoulou, V. ;

Solomon, B. J. ;

Oxnard, G. R. ;

Dziadziuszko, R. ;

Aisner, D. L. ;

Doebele, R. C. ;

Galasso, C. ;

Garon, E. B. ;

Heist, R. S. ;

Logan, J. ;

Neal, J. W. ;

Mendenhall, M. A. ;

Nichols, S. ;

Piotrowska, Z. ;

Wozniak, A. J. ;

Raponi, M. ;

Karlovich, C. A. ;

Jaw-Tsai, S. ;

Isaacson, J. ;

Despain, D. ;

Matheny, S. L. ;

Rolfe, L. ;

Allen, A. R. ;

Camidge, D. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18) :1700-1709

[4] Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development [J].

Yver, A. .

ANNALS OF ONCOLOGY, 2016, 27 (06) :1165-1170

← 1 →